Despite lower revenue forecasts, analysts see no long-term impact on the business's intrinsic value. Opinions vary, with the most optimistic analyst valuing it at US$112 and the most pessimistic at US$26.00 per share. No changes were made to next year's loss forecasts, but revenue estimates were downgraded. The company's long-term earnings trajectory is deemed more crucial than next year's performance.
Kymera Therapeutics' high P/S ratio could imply investors' bullish stance outweighs analysts. However, without major growth improvement, the high P/S value may not sustain this positive sentiment, potentially making the stock overvalued.
$キメラ・セラピューティクス(KYMR.US)$Kymera Therapeutics Announces First Patient Dosed in Phase 2 Atopic Dermatitis Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating a $15 Million Payment From Sanofi
$キメラ・セラピューティクス(KYMR.US)$Director BVF PARTNERS L P/IL purchased 414.11K shares of Common Stocks on Nov 2, 3, 2023 at an average price of $12.8019 for a total value of $5.3 million. This transaction involves other related parties: BIOTECHNOLOGY VALUE FUND L P, BVF I GP LLC, BIOTECHNOLOGY VALUE FUND II LP, BVF II GP LLC, Biotechnology Value Trading Fund OS LP, BVF Partners OS Ltd., BVF GP HOLDINGS LLC, BVF INC/IL and LAMPERT MARK N.
Though Kymera Therapeutics is increasing its cash burn and seeing reduced operating revenue, it's still well positioned. However, potential share dilution from issuing new shares to cover a year's operations could deter future investors.
$キメラ・セラピューティクス(KYMR.US)$40Million in milestone payment and not a single trade in PM? hehehe! well ima put a lowball order and see if it fills? But you better believe i got that SL tight! hehehe
$キメラ・セラピューティクス(KYMR.US)$Kymera Therapeutics Announces First Patient Dosed in Phase 2 Hidradenitis Suppurativa Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating $40 Million Payment from Sanofi 4 MINUTES AGO, 7:00 AM EDT VIA GLOBENEWSWIRE
キメラ・セラピューティクスに関するコメント
Update
Insider buy!
This transaction involves other related parties: BIOTECHNOLOGY VALUE FUND L P, BVF I GP LLC, BIOTECHNOLOGY VALUE FUND II LP, BVF II GP LLC, Biotechnology Value Trading Fund OS LP, BVF Partners OS Ltd., BVF GP HOLDINGS LLC, BVF INC/IL and LAMPERT MARK N.
Gonna get worse?
Dow Jones· 6 mins ago
Really!
News
4 MINUTES AGO, 7:00 AM EDT
VIA GLOBENEWSWIRE
コラムToday's pre-market stock movers: NVAX, MRNA, NCLH, MU and more
In reaction to earnings/guidance:
• $グッド・アール・エックス(GDRX.US)$ +38.5%,$エッジオ(EGIO.US)$ +13.5%,$レモネード(LMND.US)$ +10.7%,$デスクトップ・メタル(DM.US)$ +8.5%,$ショックウェーブ・メディカル(SWAV.US)$ +8.2%,$パブティック(PUBM.US)$ +8.1%,$オラプレックス・ホールディングス(OLPX.US)$ +7%,$ヴィヴィッド・シーツ(SEAT.US)$ +6.4%,$ノーブル(NE.US)$ +6.3%,$アスペンテクノロジーインク(AZPN.US)$ +5.4%,$AAON(AAON.US)$ +5%,$ハドベイ・ミネラルズ(HBM.US)$ +5%,$Vivint Smart Home(VVNT.US)$ +4.9%,$Vivint Smart Home(VVNT.US)$ +4...
まだコメントはありません